Call us today 212-583-0100

ENZO Biochem Names Robert Boorstein, MD, PHD, Medical Director of Enzo Clinical Labs

NEW YORK, NY, March 4, 2010 – Enzo Biochem Inc. (NYSE:ENZ) announced today that Robert Boorstein, MD, PhD, an Associate Professor of Pathology at the NYU School of Medicine, has been appointed Medical Director of Enzo Clinical Labs, a full service clinical reference laboratory serving the metropolitan New York City medical community.
“The appointment of Dr. Boorstein, a highly regarded pathologist who until recently was Director of Pathology at the world renowned Bellevue Hospital Center, to our staff is a major addition to our Lab, and is in keeping with the ongoing transformative program we have underway to broaden and diversify its scope, ” said Dr. Kevin Krenitsky, President of Enzo Clinical Labs.
“Dr. Boorstein brings with him over 25 years of particularly rich experience as a pathologist and medical laboratory director  that will enable us to continue our program to forge ahead in providing the latest state-of-the-art diagnostic testing procedures,” added Dr. Krenitsky.
Dr. Boorstein received his M.D. from Harvard Medical School, along with a M.A. and PhD in Pharmacology from Harvard University, and a B.A. summa cum laude, from the same University.   Following his residency in pathology at the NYU School of Medicine, he remained on the faculty and subsequently became Director of Pathology at Bellevue Hospital/NYU Shared Laboratories.  In this position, he directed the consolidation of laboratories within the South Manhattan and North Manhattan Healthcare Networks of the NYC Health and Hospital Corporation, and oversaw the expansion and modernization of the Bellevue Hospital laboratory.  He has also been associated with Tisch Hospital and served as Director of Pathology at Lincoln Hospital, in addition to spending a year as a Visiting Scholar at Laboratoire de Chimie, C.E.N.G., Grenoble, a research institution in France.   He has been associated with numerous professional groups and committees, and has written extensively for professional journals.  He is widely recognized for his expertise in technology assessment and the linkage of diagnostics and therapeutics.
About Enzo
Enzo Biochem, Inc., is a growth-oriented integrated life sciences and biotechnology company focused on harnessing biological process to develop research tools, diagnostics and therapeutics, and serves as a provider of test services, including exotic tests, to the medical community.  Since our founding in 1976, our strategic focus has been on the development of enabling technologies in the life sciences field.  Enzo Life Sciences develops, produces and markets proprietary labeling and detection products for gene sequencing, genetic analysis and immunological research, among others. Its catalog of over 40,000 products serve the molecular biology, drug discovery and pathology research markets worldwide.  Enzo Clinical Labs division provides laboratory services for a growing roster of physicians in the New York Metropolitan area, as well as parts of New Jersey and Pennsylvania.  Its tests include, in addition to routine tests, capabilities for detecting molecular infection disease, molecular oncology, autoimmune disorders and genetics.  Enzo Clinical Labs also provides clinical diagnostic services that allow Enzo to capitalize on its extensive advanced molecular and cytogenetic capabilities and the broader trends in predictive and personalized diagnostics.  Enzo Therapeutics is a biopharmaceutical venture that has developed multiple novel approaches in the areas of gastrointestinal, infectious, ophthalmic and metabolic diseases.  It has focused its efforts on developing treatment regimens for diseases and conditions for which current treatment options are ineffective, costly, and/or cause unwanted side effects.  In the course of the company’s research and development activities, Enzo has developed a substantial portfolio of intellectual property assets, with 249 issued patents worldwide and over 200 pending patent applications.
Except for historical information, the matters discussed in this news release may be considered "forward-looking" statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. Such statements include declarations regarding the intent, belief or current expectations of the Company and its management. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve a number of risks and uncertainties that could materially affect actual results. The Company disclaims any obligations to update any forward-looking statement as a result of developments occurring after the date of this press release.
     For: Enzo Biochem, Inc.
     Steven Anreder, 212-532-3232       or    Michael Wachs, CEOcast, Inc., 212-732-4300